MEDICAL SYSTEM NETWORK Co., Ltd.

Second Quarter (Interim) of Fiscal Year Ending March 2025 Standard Market of Tokyo Stock Exchange; Securities Code: 4350

Data Book

(November 8, 2024)



Table of Contents

 Consolidated Statement of Income and Comprehensive Income Consolidated Statement of Income Consolidated Statement of Comprehensive Income 	• • • 1
2 . Consolidated Balance Sheet	• • • 3
3. Consolidated Statement of Cash Flows	4
4. Key Financial Indicators (consolidated)	• • • 5
5. Dividends	• • • 5
6 . No.of Employees (consolidated)	• • • 5
7. Community Pharmacy Network Segment (1) Community Pharmacy Business (2) Pharmaceutical Network Business	• • • 6
8. Consolidated Earnings Forecast	• • • 8

■ About contents covered

- X The contents of this report pertaining future earnings described are based on information the company has held, and on certain assumptions supervising rational judgement, and are not what the company promises to achieve. There are numerous factors that may cause actual earnings to differ.
- % Caution is given to the accuracy of information, and we do not take responsibility for loss etc., as a result of misinformed information.
- \times Furthermore, this report is not prepared for the purposes of investment solicitation. Readers are responsible for their own judgement in any decision regarding investments.

1. Consolidated Statement of Income and Comprehensive Income

(1) Consolidated Statement of Income

	FY3/2023	FY3/	2024	FY3/2025		
	Interim	Interim 4/2023 - 9/2023		Inte		
	4/2022 - 9/2022				- 9/2024	
	4/2022 - 9/2022	4/2023 -	Change	4/2024	Change	
Net sales	E2 240	EG 464		E0 764		
(YoY)	53,340 2.2%	56,461 5.9%	3,121	59,761 5.8%	3,300	
Community Pharmacy Network Segment	50,792	53,765	2,972	57,074	3,308	
Leasing and Facility related Segment	1,673	1,687	2,972	1,729	3,306	
Meal Catering Segment	1,135	1,189	54		(12)	
	1,135	1,169	34	1,177 174	18	
Home Visit Nursing Segment			75		(57)	
Adjustments Cost of sales	(412) 31,024	(336) 33,008	1,983	(394) 35,097	2,089	
(% of Net sales)	·	58.5%	1,963	-	2,089	
	58.2%		4 407	58.7%	4 044	
Gross profit (YoY)	22,315	23,453	1,137	24,664	1,211	
	2.1%	5.1%	_	5.2%	_	
(% of Net sales)	41.8%	41.5%	- 504	41.3%	4 000	
SG&A expenses (% of Net sales)	21,215	21,740	524	23,636	1,896	
, ,	39.8%	38.5%	-	39.6%		
Labor costs	12,258	12,520	261	13,406	886	
Depreciation	584	633	48	754	120	
Amortization of goodwill	565	561	(3)	588	26	
EBITDA	2,537	3,247	710	2,697	(549)	
Operating profit (YoY)	1,099	1,712	612	1,027	(684)	
(% of Net sales)	(40.9%)	55.7%	_	(40.0%)		
	2.1%	3.0%		1.7%	(706)	
Community Pharmacy Network Segment	2,384	*2 2,947	563	2,241	(706)	
Leasing and Facility related Segment	(65)	* 2 69	134	99	29	
Meal Catering Segment	(33)	(23)	10	(7)	15 8	
Home Visit Nursing Segment	(10)	(20)	(9)	(12)	,	
Adjustments	(1,175)	(1,261)	(85)	(1,293)	(32)	
Non-operating profit	325	179	(146)	180	0	
Interest income and Dividend income		176	(0)		0	
Other		176	(146)	176 187		
Non-operating expenses	182	199	17 18		(11)	
Interest expenses	138 43	157 42		130 57	(26) 14	
Other			(1) 449			
Ordinary profit (YoY)	1,242 (44.4%)	1,692 36.2%	449	1,020 (39.7%)	(672)	
(% of Net sales)	(44.4%)	30.2%	_	(39.7%)	_	
Extraordinary income	2.3%	3.0%		1.7%	33	
Extraordinary Income Extraordinary losses	85	9	(75)	239	229	
Profit before income taxes	1,165	1,705	(75) 540	239 837	(868)	
Income taxes	653	839	186	615	(223)	
Profit attributable to non-controlling interests	10	5		14	(223)	
Profit attributable to owners of parent	502	861	(4) 359	207	(654)	
(YoY)			339		(004)	
	(64.9%)	71.5%	_	(76.0%)	_	
(% of Net sales)	0.9%	1.5%	_	0.3%	_	

X1 Includes subsidy income of 114 million for online eligibility verification.

[&]amp;2 From FY3/2024, transfer of expenses related to pharmacy development from the leasing and equipment-related business to the community pharmacy sector 78 million yen.

(2) Consolidated Statement of Comprehensive Income

	FY3/2023	FY3/	2024	FY3/	2025
	Interim	Inte	Interim		erim
	4/2022 - 9/2022	4/2023 -	- 9/2023	4/2024	- 9/2024
			Change		Change
Profit	512	866	354	221	(645)
Other comprehensive income	11	25	14	11	(14)
Valuation difference on available-for-sale securities	0	12	12	(2)	(15)
Deferred gains or losses on hedges	1	0	(1)	0	0
Remeasurements of defined benefit plans, net of tax	9	12	3	13	0
Comprehensive income	523	892	368	232	(659)
(YoY)	(63.9%)	70.3%	_	(73.9%)	_
Comprehensive income attributable to owners of parent	513	887	373	218	(668)
Comprehensive income attributable to non-controlling interests	10	5	(4)	14	9

2. Consolidated Balance Sheet

	FY3/2024	FY3/	2024	FY3/2025			
	Interim	1 10/	2021	Interim			
	End of 9/2023	End of	3/2024		9/2024		
	Liid 01 3/2023	Liid oi	Change	Liid Oi	Change		
Total current assets	19,668	20,773	1,104	22,173	1,399		
Cash and deposits	7,643	8,273	629	·	416		
Accounts receivable - trade	3,676	4,239	563	, i	89		
Inventories	5,720	5,541	(178)	6,434	892		
Other	2,628	2,718	89	· ·	0		
Total non-current assets	46,586	47,376		,	427		
Property, plant and equipment	28,128	28,336	207	28,987	650		
Buildings and structures, net	13,285	12,996	(289)	13,428	432		
Land	9,031	9,290	258	· ·	3		
Leased assets	4,114	4,184	70		(85)		
Construction in progress	145	325	179	366	41		
Other	1,551	1,539	(11)	1,798	259		
Intangible assets	11,272	11,281	9	10,726	(554)		
Goodwill	10,622	10,613	(8)	9,944	(668)		
Other	650	668	18		113		
Investment and other assets	7,185	7,759	573	8,090	331		
Investment securities	177	184	7	180	(4)		
Guarantee deposits	3,303	3,419	116		367		
Deferred tax assets	2,927	3,339	412	3,266	(73)		
Other	777	815	37	856	40		
Total assets	66,255	68,149	1,894		1,826		
Total current liabilities	22,158	23,213	1,055		4,834		
Accounts payable - trade	10,135	10,935	799		(135)		
Short-term borrowings	1,136	588	(548)	5,339	4,751		
Current portion of long-term	4,905	5,122	217	4,567	(555)		
Lease obligations	390	406	15	418	12		
Income taxes payable	687	999	312	533	(466)		
Other	4,903	5,160	257	6,389	1,228		
Total non-current liabilities	28,899	29,716	816	26,659	(3,057)		
Long-term borrowings	17,843	18,309		15,188	(3,121)		
Lease obligations	4,687	4,754	67	4,646	(108)		
Provision for retirement benefits for	648	691	43	690	(0)		
directors (and other officers)	040	091	43	090	(0)		
Retirement benefit liability	4,299	4,534	234	4,709	175		
Other	1,420	1,426	5	1,424	(2)		
Total liabilities	51,057	52,930	1,872	54,708	1,777		
Shareholders' equity	15,268	15,284	15	15,307	23		
Share capital	2,128	2,128	_	2,128	_		
Capital surplus	1,182	937	(245)	946	9		
Retained earnings	12,284	13,100	816	13,124	23		
Treasury shares	(326)	(882)	(555)	(891)	(9)		
Accumulated other comprehensive	(113)	(112)		(101)	11		
income	(113)	(112)		(101)	11		
Non-controlling interests	42	47	5		14		
Total net assets	15,197	15,219	21	15,268	49		

3. Consolidated Statement of Cash Flows

			(million yen)
	FY3/2023	FY3/2024	FY3/2025
	Interim	Interim	Interim
	4/2022 - 9/2022	4/2023 - 9/2023	4/2024 - 9/2024
Cash flows from operating activities	1,701	3,611	517
Profit before income taxes	1,165	1,705	837
Depreciation	872	972	1,08
Impairment loss	18	5	223
Amortization of goodwill	565	561	588
Increase (decrease) in provision	265	261	180
Loss(gain)on disposal of assets and valuation of securities	39	(21)	(39
Interest and dividend income, Interest expenses	135	131	127
Decrease (increase) in notes and accounts receivable - trade	(437)	(239)	(53
Decrease (increase) in inventories	(456)	(470)	(904
Increase (decrease) in notes and accounts payable - trade	150	198	(167
Other	91	1,279	(211
Subtotal	2,410	4,385	1,661
Interest and dividend income received, interest expenses paid	(136)	(130)	(130
Income taxes paid	(572)	(644)	(1,014
Cash flows from investing activities	(902)	(1,209)	(785
Purchase of tangible fixed assets	(670)	(968)	(1,456
Proceeds from sales of tangible fixed assets	22	0	9
Purchase of intangible fixed assets	(156)	(122)	(205
Purchase of shares of subsidiaries resulting in change in scope of consolidation	_	_	(14
Proceeds from sale of businesses	_	31	1,547
Payments of loans receivable	(0)	(1)	(170
Collection of loans receivable	3	1	(
Payments for guarantee deposits	(49)	(132)	(442
Proceeds from collection of guarantee deposits	30	35	56
Other	(81)	(54)	(110
Cash flows from financing activities	(2,226)	(2,899)	685
Net increase (decrease) in short-term loans payable	500	120	4,75
Repayments of long-term loans payable	(2,392)	(2,630)	(3,676
Repayments of lease obligations	(120)	(205)	(211
Proceeds from share issuance to non-controlling shareholders	(213)	(182)	(177
Net increase (decrease) in cash and cash equivalents	(1,427)	(497)	410
Cash and cash equivalents at beginning of period	8,171	8,111	8,242
Cash and cash equivalents at end of period	6,743	7,613	8,659

4. Key Financial Indicators (consolidated)

	FY3/2024 Interim 4/2023 - 9/2023	FY3/2024 4/2023 - 3/2024	FY3/2025 Interim 4/2024 - 9/2024
No.of Shares outstanding (including treasury stocks)	30,642,600	30,642,600	
No.of Shares outstanding (excluding treasury stocks)	30,178,545	29,228,545	29,228,545
Stock price as of the end of the period (yen)	408	665	433
Market cap (million yen)	12,312	19,436	12,655
EPS (yen)	28.54	61.89	7.08
BPS (yen)	502.18	519.06	520.26
PER (times)	_	10.7	_
PBR (times)	0.8	1.3	0.8
ROE (%)	_	12.6	_
ROA (%)	_	5.7	_
Equity ratio (%)	22.9	22.3	21.7

5. Dividends <plan>

	FY3/2023	FY3/2024	FY3/2025
Annual dividend (yen)	12.00	12.00	12.00
Interim (yen)	6.00	6.00	6.00
Year-end (yen)	6.00	6.00	6.00
Total dividends (million yen)	366	361	357
Payout ratio (%)	22.5	19.4	28.1
Dividend yield (%)	3.0	1.8	-

6. No.of Employees (consolidated)

(persons)

	FY3/2024	FY3	FY3/2	FY3/2025			
	Interim			Inter			
	End of 9/2023	End of	3/2024	End of 9			
			Change		Change		
Community Pharmacy Network Segment	3,741	3,794	53	3,959	165		
Full-time employees	3,231	3,267	36	3,399	132		
(Pharmacists)	1,555	1,529	(26)	1,589	60		
Temporary employees	510	527	17	560	33		
(Pharmacists)	288	296	8	309	13		
Leasing and Facility related Segment	152	146	(6)	138	(8)		
Full-time employees	140	134	(6)	127	(7)		
Temporary employees	12	12	0	11	(1)		
Meal Catering Segment	406	398	(8)	396	(2)		
Full-time employees	167	160	(7)	171	11		
Temporary employees	239	238	(1)	225	(13)		
Home Visit Nursing Segment	57	59	2	58	(1)		
Full-time employees	44	46	2	44	(2)		
Temporary employees	13	13	0	14	1		
Corporate	152	149	(2)	167	18		
Full-time employees	139	137	(2)	153	16		
Temporary employees	13	12	(0)	14	2		
Total	4,507	4,546	39	4,718	172		
Full-time employees	3,721	3,744	23	3,894	150		
Temporary employees	786	802	16	824	22		

^{**}The number of full-time employees is as of the end of each fiscal year. The number of temporary employees is yearly average number of persons employed based on 8-hour conversion.

7. Community Pharmacy Network Segment

(1) Community Pharmacy Business

①No.of pharmacies

© 140.00 production of the control o													
		FY3	/2023			FY3/2024			FY3/2025				
										Interim			
		4/2022	- 3/2023			4/2023	- 3/2024			4/2024	- 9/2024		
	Openings	M & A	Closings Transfers	End of FY	Openings	M & A	Closings Transfers	End of FY	Openings	M & A	Closings Transfers	End of FY	
No.of pharmacies	8	2	7	428	13	18	9	450	11	1	10	452	
Hokkaido area	2	_	4	122	3	_	5	120	3	1	1	123	
Tohoku area	_	_	_	24	1	7	_	32	_	_	1	31	
Kanto/Koshinetsu area	3	2	_	101	5	1	2	105	4	_	3	106	
Tokai/Hokuriku area	_	_	_	44	_	_	_	44	_	_	_	44	
Kinki area	3	_	3	53	1	_	2	52	4	_	1	55	
Chugoku/Shikoku area	_	_	_	21	1	_	_	22	_	_	_	22	
Kyushu area	_	_	_	63	2	10	_	75	_	_	4	71	
Care plan centers	_	_	_	1	_	_	_	1	_	_	_	1	
Drug/cosmetic stores	-	-	-	9	1	_	1	9	_	_	_	9	

②Dispensing fee breakdown (No.of prescriptions / Unit price)

© Dispensing fee breakdown (No.0) prescriptions / Offic price/											
	FY3/2023		FY3/2024			FY3/2025					
	Interim		Interim			Interim					
	4/2022 - 9/2022		4/2023 - 9/2023			4/2024 - 9/2024					
			Change	Change(%)		Change	Change(%)				
No.of prescriptions(a)(1,000)	4,517	4,777	7 260 5.8%		4,947	169	3.6%				
Unit price(b) (ye	n) 10,061	10,033	(28) (0.3%)		10,228	195	1.9%				
Drug charge per prescription	7,634	7,687	54	0.7%	7,828	140	1.8%				
Technical fee per prescription	2,427	2,346	(81)	(3.3%)	2,400	54	2.3%				
Dispensing fee(a)×(b)(million ye	n) 45,448	47,935	2,487	5.5%	50,600	2,664	5.6%				

③Dispensing fee breakdown by new openings and M&A period

(million yen)

	FY3/	2024		FY3/2025	
	Inte	erim		Interim	
	4/2023 -	- 9/2023		4/2024 - 9/2024	
		% of Net sales		% of Net sales	Change
Dispensing fee	47,935	100.0%	50,600	100.0%	2,664
Existing pharmacies (Openings~2023.3)	47,116	98.3%	47,805	94.5%	688
New openings (4/2023~3/2024)	111	0.2%	443	0.8%	331
M&A (4/2023~3/2024)	_	_	1,610	3.2%	1,610
New openings (4/2024~9/2024)	_	_	500	1.0%	500
M&A (4/2024~9/2024)	_	_	62	0.1%	62
Closings / Transfers	707	1.5%	178	0.4%	(528)

Monthly dispensing fee (All / Existing) (YoY)

(%)

All pharmacies (YoY)	4/2024	5/2024	6/2024	7/2024	8/2024	9/2024	FY3/2025
							1st half total
Dispensing fee	9.7	7.6	0.8	11.8	1.4	2.6	5.6
No.of prescriptions	9.3	5.7	(1.7)	7.6	0.9	(0.2)	3.6
Unit price	0.3	1.8	2.5	3.9	0.4	2.8	1.9

Existing pharmacies (YoY)	4/2024	5/2024	6/2024	7/2024	8/2024	9/2024	FY3/2025
							1st half total
Dispensing fee	6.1	4.1	(2.9)	7.1	(3.3)	(1.9)	1.5
No.of prescriptions	4.9	1.1	(5.7)	3.0	(3.5)	(4.4)	(0.8)
Unit price	1.1	2.9	3.0	4.0	0.2	2.7	2.3

^{*}Existing pharmacies definition: Pharmacies that have been continuously open since April 1,2023 for the current FY

(2) Pharmaceutical Network Business

①No.of Network affiliates

	FY	/3/2024 (End of 3/20	024)	FY3/2025 (End of 9/2024)		
Attribute	MSNW	General		MSNW	General	
	community	network	Total	community	network	Total
Area	pharmacies	affiliates		pharmacies	affiliates	
Hokkaido	120	240	360	123	229	352
Tohoku	32	655	687	31	722	753
Kanto/Koshinetsu	105	2,908	3,013	106	3,183	3,289
Tokai/Hokuriku	44	1,594	1,638	44	1,664	1,708
Kinki	52	1,547	1,599	55	1,674	1,729
Chugoku/Shikoku	22	963	985	22	997	1,019
Kyushu/Okinawa	75	1,399	1,474	71	1,514	1,585
Total	450	9,306	9,756	452	9,983	10,435

②Pharmaceuticals transactions volume

C. Manual Juliana Manual Manua							(11111110111)
	FY3/2023	FY3/2024			FY3/2025		
	Interim	Interim			Interim		
	4/2022 - 9/2022	4/2023 - 9/2023			4/2024 - 9/2024		
			Change	Change(%)		Change	Change(%)
Pharmaceuticals transactions volume	249,358	303,527	54,168	21.7%	328,894	25,366	8.4%

8. Consolidated Earnings Forecast

	FY3/	2024	FY3/2025		
	4/2023~3/2024		4/2024~3/2025		
	Results	% of Net sales	Forecast ※1	% of Net sales	(YoY)
Net sales	115,361	100.0%	122,000	100.0%	5.8%
Community Pharmacy Network Segment	109,904	95.3%	116,352	95.4%	5.9%
Leasing and Facility related Segment	3,611	3.1%	3,493	2.9%	(3.3%)
Meal Catering Segment	2,360	2.0%	2,358	1.9%	(0.1%)
Home Visit Nursing Segment	314	0.3%	343	0.3%	9.2%
Adjustments	(828)	-	(548)	-	-
Gross profit	47,925	41.5%	50,998	41.8%	6.4%
SG&A expenses	44,093	38.2%	47,998	39.3%	8.9%
Labor costs	25,279	21.9%	26,962	22.1%	6.7%
Depreciation	1,356	1.2%	1,684	1.4%	24.2%
Amortization of goodwill	1,132	1.0%	1,162	1.0%	2.6%
EBITDA	6,997	6.1%	6,440	5.3%	(8.0%)
Operating profit	3,832	3.3%	3,000	2.5%	(21.7%)
Community Pharmacy Network Segment	6,433	※ 2 5.9%	5,531	※ 2 4.8%	(14.0%)
Leasing and Facility related Segment	158	※ 2 4.4%	192	※ 2 5.5%	21.6%
Meal Catering Segment	(43)	-	32	※ 2 1.4%	-
Home Visit Nursing Segment	(43)	-	(24)	-	-
Adjustments	(2,671)	-	(2,732)	-	-
Ordinary profit	3,825	3.3%	3,000	2.5%	(21.6%)
Profit attributable to owners of parent	1,860	1.6%	1,250	1.0%	(32.8%)

^{※1} Revised full-year forecasts on 31 October 2024.

^{%2 %} of Segment sales



【Contact us】

MEDICAL SYSTEM NETWORK Co., Ltd. Corporate Management Division

E-mail: info@msnw.co.jp